Treat Adult Plaque Psoriasis | VTAMA® (tapinarof) cream, 1%

Most prescribed branded topical treatment for plaque psoriasis in adults*

Join the thousands of prescribers who
have already chosen VTAMA cream.

NUMBERS DON'T LIE. VTAMA cream is the most prescribed
branded topical treatment for adults with plaque psoriasis*

425,000+

prescriptions since launch^†

16,000+

unique prescribers^†

5,000+

U.S. pharmacies where MyVTAMA^TM
savings card has been redeemed¹

*IQVIA National Prescription Audit (NPA) for the 3-month period ending 7/26/2024, reflecting estimates of real-world activity. All rights reserved.
^†IQVIA National Prescription Audit (NPA) for the period 5/20/22 to 7/26/2024, reflecting estimates of real-world activity. All rights reserved.

Safety & Tolerability

Patient Experience

NUMBERS DON'T LIE. VTAMA cream is the most prescribed branded topical treatment for plaque psoriasis in adults*

425,000+

prescriptions since launch^†

16,000+

unique prescribers^†

5,000+

U.S. pharmacies where MyVTAMA^TM savings card has been redeemed¹

*IQVIA National Prescription Audit (NPA) for the 3-month period ending 7/26/2024, reflecting estimates of real-world activity. All rights reserved.
^†IQVIA National Prescription Audit (NPA) for the period 5/20/22 to 7/26/2024, reflecting estimates of real-world activity. All rights reserved.

Why VTAMA cream?

VTAMA cream is a once-daily, steroid-free treatment for plaque psoriasis in adults²

VTAMA (tapinarof) cream tube

6x the Efficacy vs Vehicle

In two 12-week pivotal studies, the Physician Global Assessment (PGA) success^‡ rate was 36% and 40% for patients using VTAMA cream vs 6% and 6% for patients on vehicle.²
~4 Month Off-Treatment Effect

In an open-label, long-term extension study, the median time to PGA≥2 was 114 days (n=73).^2,3
Favorable Safety and Tolerability

In clinical studies, VTAMA cream showed a favorable and consistent safety profile and was well tolerated, even on sensitive areas of skin.^3-5
^‡PGA success: PGA score of 0 or 1 and ≥2-grade improvement from baseline at week 12.

VTAMA (tapinarof) cream tube

References: 1. Dermavant DOF [MyVTAMA Pharmacy Count; Jan 2023]. 2. VTAMA (tapinarof) cream, 1%. Prescribing Information. Dermavant; 2022. 3. Strober B, Stein Gold L, Bissonnette R, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J Am Acad Dermatol. 2022;87(4):800-806. 4. Stein Gold L, Kircik L, Lebwohl M, et al. Tapinarof cream 1% once daily for plaque psoriasis: favorable local tolerability in two pivotal phase 3 trials. Poster presented at: Innovations in Dermatology Conference; March 16–20, 2021; virtual. 5. Lebwohl M, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385(24):2219-2229. 6. Dermavant DOF. CSR-DMVT-505-3001. A phase 3 efficacy and safety study of tapinarof for the treatment of plaque psoriasis in adults. 2020. 7. Dermavant DOF. CSR-DMVT-505-3002. A phase 3 efficacy and safety study of tapinarof for the treatment of plaque psoriasis in adults. 2020. 8. Stein Gold L, Blauvelt A, Armstrong A, et al. Tapinarof cream 1% once daily for plaque psoriasis: secondary efficacy outcomes from two pivotal phase 3 trials. Poster presented at: International Federation of Psoriasis Associations; June 30–July 3, 2021; virtual. 9. Dermavant DOF. PSOARING Patient Images. 2022. 10. Bissonnette R, Strober B, Lebwohl M, et al. Tapinarof cream 1% once daily for plaque psoriasis: patient-reported outcomes from two pivotal phase 3 trials. Poster presented at: American Academy of Dermatology; March 19–23, 2021; San Francisco, CA. 11. Dermavant DOF. CSP-DMVT-505-3001. A phase 3 efficacy and safety study of tapinarof for the treatment of plaque psoriasis in adults. 2019. 12. Bissonnette R, Stein Gold L, Rubenstein DS, Tallman AM, Armstrong A. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor—modulating agent. J Am Acad Dermatol. 2021;84(4):1059-1067. 13. Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137:2110-2119. 14. Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082. 15. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. 16. Kim BE, Howell MD, Guttman E, et al. TNF-α downregulates filaggrin and loricrin through c-Jun N-terminal kinase: role for TNF-α antagonists to improve skin barrier. J Invest Dermatol. 2011;131:1272-1279. 17. Cannavò SP, Riso G, Casciaro M, Di Salvo E, Gangemi S. Oxidative stress involvement in psoriasis: a systematic review. Free Radic Res. 2019;53(8):829-840. 18. Dietrich C. Antioxidant functions of the aryl hydrocarbon receptor. Stem Cell Int. 2016:7943495. 19. Dermavant DOF. The effect of GSK2894512 on the Th2 polarization of human CD4+ T cells and on IL-8 release from TLR2-stimulated keratinocytes. 2015. 20. Bissonnette R, Poulin Y, Zhou Y, et al. Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week multicentre, randomized, placebo-controlled double-blind trial. Br J Derm. 2012;166(4):853-860. 21. Bagel J, Stein Gold L, Del Ross J, et al. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial. J Am Acad Dermatol. 2023;89:936-44. 22. Dermavant DOF. GSK2894512A: Formulation Development Report. 2018. 23. Sofen H, Tyring S, Johnson SM, et al. Efficacy of tapinarof cream 1% once daily for the treatment of mild to severe intertriginous plaque psoriasis. Poster presented at: Fall Clinical Dermatology Conference; October 19-22, 2023; Las Vegas, NV. 24. Sofen H, Tyring S, Johnson SM, et al. Tapinarof cream 1% once daily improves patient-reported outcomes in the treatment of mild to severe intertriginous plaque psoriasis. Poster presented at: Fall Clinical Dermatology Conference; October 19-22, 2023; Las Vegas, NV. 25. Dermavant DOF. DMVT-505-4001 iPsO Patient Images. 2023 26. Strober B, Stein Gold L, Bissonnette R, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial. J Am Acad Dermatol. 2022; 87:800-806. 27. Dermavant DOF. CSR-DMVT-505-3003. A long-term, open-label extension study to evaluate the safety and efficacy of tapinarof cream, 1% for the treatment of plaque psoriasis in adults. 2021. 28. Dermavant DOF. PSOARING 3 entering with or achieving PGA 0 or 1; Jan 2024. 29. Stein Gold L, Lewitt GM, Lockshin B, et al. Tapinarof cream 1% once daily is efficacious in the treatment of mild to severe plaque psoriasis in the head and neck region. Poster presented at: Winter Clinical Dermatology Conference; January 12-17, 2024; Honolulu, HI. 30. Lewitt GM, Stein Gold L, Lockshin B, et al. Tapinarof 1% cream improves patient-reported outcomes in the treatment of mild to severe plaque psoriasis in the head and neck region. Poster presented at: Winter Clinical Dermatology Conference; January 12-17, 2024; Honolulu, HI. 31. Dermavant DOF. 4002 Head & Neck Plaque Psoriasis Phase 4. 2023.

Back to top